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Abstract: DNA damage to cells activates nuclear poly(ADP-ribose)polymerases (PARPs) 
and the poly(ADP-ribose) (PAR) synthesized is rapidly cleaved into ADP-ribose (ADPR) 
by PAR glycohydrolase (PARG) action. Naturally appearing tannin-like molecules have 
been implicated in specific inhibition of the PARG enzyme. This review deals with the in 
vitro and in vivo effects of tannins on PAR metabolism and their downstream actions in 
DNA damage signaling. 
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1. The Impact of Poly(ADP-Ribose) Metabolism 
The poly(ADP-ribosyl)ation of proteins is an early step in the initiation of DNA damage processing 
and cell death. The nuclear enzymes poly(ADP-ribose)polymerase-1 (PARP-1, EC 2.4.2.30, see [1] for 
nomenclature details) and to a lesser extent PARP-2 (EC 2.4.2.30) react to DNA nicks which occur 
after genotoxic stress within seconds, activating their catalytic activities and thereby producing large 
amounts of poly(ADP-ribose) (PAR) [2-5]. The substrate for this reaction is the respiratory coenzyme 
nicotinamide adenine dinucleotide (NAD+). The PARPs cleave NAD+ into ADP-ribose (ADPR), 
nicotinamide and H+, and catalyze the assembly of large negatively charged ADPR polymers with a 
branching frequency of up to 3% (Figure 1). The synthesis of PAR requires three distinct enzymatic 
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activities: (1) initiation or mono(ADP-ribosyl)ation of the substrate, (2) formation of the PAR 
polymer, and (3) branching of the polymer. While over 90% of PAR is covalently bound to specific 
PARP enzymes, some PAR is linked to other proteins [3,6,7]. So far, the nuclear enzymes PARP-1 and 
PARP-2 are the sole members of the still growing family of PARP enzymes [6], whose catalytic 
activity is stimulated by DNA damage in vitro and in vivo, suggesting an integral role in the response 
to genotoxic insults [2,7-10]. About 99% of PAR is synthesized by PARP-1 after genotoxic stress 
demonstrating the dominant role of this enzyme in PAR metabolism [2,11]. 
 
Figure 1. Poly(ADP-ribose) metabolism. In response to DNA damage, nuclear  
poly(ADP-ribose)polymerases (PARP-1 and PARP-2) hydrolyze NAD+, releasing ADPR, 
nicotinamide and H+. This reaction is induced by the formation of an ester bond between 
the amino acid-acceptors glutamic acid, aspartic acid or COOH-lysine and the first  
ADP-ribose (ADPR, marked in blue). Elongation occurs at the 2′-OH of the ribose moiety 
whereas branching occurs at the 2″-OH position resulting in poly(ADPR) (PAR), a  
multi-branched polyanion. Poly(ADPR)glycohydrolase (PARG) is a catabolic enzyme with 
an endo- and exoglycosidic activity. It cleaves the glycosidic bonds between the ADPR 
units, resulting in free PAR and finally ADPR. 
 
Molecules 2011, 16 
  
1856
The degradation of PAR is catalyzed mainly by PARG (PAR glycohydrolase, EC 3.2.1.143), an 
enzyme, with both exo- and endoglycosidic activities, hydrolyzing the glycosidic bond between ADPR 
units. PARG liberates primarily ADPR via exoglycosidic action, along with few free PAR chains from 
endoglycosidic action [12,13]. Branched and short PAR molecules are degraded slowly and with lower 
affinities by PARG (KM ≈ 10 µM) than long and linear polymers (KM = 0.1-0.4 µM) [14]. PARPs and 
PARG cooperate very closely in the response to DNA damage and imbalances between these enzyme 
activities dramatically alter the outcome of genotoxic stress, i.e. cell survival or death  
[3,6,12,15-17]. An overview of PAR metabolism is presented in Figure 1. The accumulation of PAR at 
sites of DNA damage recruits DNA damage repair proteins such as ATM, DNA ligase III, Ku70, 
MRE11, NBS1, and XRCC1 [18-21]. PAR also targets proteins involved in the epigenetic control of 
chromatin functions, such as histones, DNA methylation enzymes and transcription factors (reviewed 
in [22-25]). Recently, a distinct role for PAR, and its final cleavage product ADPR in Ca2+-mediated 
cell death has been elucidated [26-30]. 
The role of PARPs has been extensively studied in different genetic ablation models and more 
importantly, chemical inhibitors have found clinical acceptance recently [31-36]. In contrast, the 
detailed function of PARG remains still unclear. A single gene in mice and humans encodes PARG. 
Following transcription, several splicing products emerge that are translated into several proteins of 
different molecular sizes, subcellular localizations and the abilities to cleave PAR. In murine cells, the 
full-length 110 kDa PARG (mPARG110) is present in the cytoplasm and the nucleus and it accounts 
for most of the PARG activity. However, a shorter PARG protein (mPARG63) is described with 
ubiquitous distribution and mPARG58 localizes within the mitochondria [37-39]. In human cells, 
PARG exists at least in five different splicing variants [38-40]. Full-length hPARG111/110 is nuclear, 
two shorter isoenzymes hPARG103/102 and hPARG99 localize extra-nuclearly, and hPARG55 was 
found in mitochondria. Besides, hPARG60 has been shown in various localizations. 
2. Lessons Learned from Genetic parg Knock-Out and Knock-Down Mice 
The genetic modulation of PARG helped understand distinct biological functions of PARG 
isoforms. Interestingly, mice homozygous for complete knock-out of parg gene show an early 
embryonic lethal phenotype due to PAR accumulation [41]. Trophoblast stem cell lines derived from 
these parg-null embryos need the presence of PARP inhibitors to survive and proliferate. Moreover, 
these cells are hypersensitive to an alkylating agent and menadione. The genetic disruption of the parg 
gene enhances the level of PAR-modification of histones H1, H2A, and H2B, increases DNA 
accessibility in chromatin for MNase and acridine orange, and enhances DNA damage by  
N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) and UV radiation [42]. These damage types remain 
unrepaired within 12 h. Parg-null trophoblasts show an increased level of cell death induced by the 
chemotherapeutic drugs epirubicin, cisplatin, and cyclophosphamide. 
Depletion of the full-length nuclear form of the murine parg gene by deletion of exons 2 and 3 
produces viable and fertile mice. The animals are characterized by a hypersensitivity to genotoxic 
stress and endotoxin-induced shock and are partially protected against renal and splanchnic 
ischemia/reperfusion damage (I/R) [37,43,44]. Embryo fibroblasts from these mice show 
hypersensitivity against genotoxic stress, develop more sister chromatid exchanges (SCE), contain 
more micronuclei and chromosomal aberrations and display abnormal centrosome amplification with a 
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parallel accumulation of S-phase cells after aphidicolin-1 (Aph-1, replication poison) treatment 
compared with their wildtype counterparts. Moreover, PARG110-/- cells accumulate more Rad51 foci in 
response to hydroxyurea. The observed defects in repair of replication fork damage could be the cause 
of higher rates of diethylnitrosamine-induced hepatocellular carcinoma in PARG110-/- mice [45]. 
Following DNA damage by MNNG, PARG110-/- cells display reduced formation of XRCC1 foci, 
delayed H2AX phosphorylation, reduced amounts of DNA break intermediates during repair, and an 
increased rate of cells undergoing cell death [46]. 
Two studies from Meyer-Ficca et al. [47,48] report that male PARG110-/- mice are sub-fertile with 
abnormalities in nuclear condensation due to unusual removal of core histones, histone H1 linker-like 
nucleoproteins and TP2 prior to sperm maturation leading to abnormally shaped sperm nuclei with 
DNA strand breaks. 
3. RNAi Technologies against PARG in Mammalian Cells 
The use of RNAi approaches to abolish PARG protein in a variety of mammalian cells led to a 
diversity of results pending on cell type and stressor applied [15-17,30,49]. HeLa cells were 
transfected with sh-RNA against PARG [49]. This treatment increased radiosensitivity concomitant 
with defects in the repair of single- and double-strand DNA breaks. Irradiated PARG-deficient HeLa 
cells have abnormal centrosome amplification inducing either polyploidy or cell death by mitotic 
catastrophe. Plasmid based gene silencing of PARG in human A549 cells retarded the rate of single-
strand break repair after H2O2 and reduced the number of surviving cells after a lethal application of 
this compound [15]. However, data from our group in murine embryonic fibroblasts (MEFs) using 
transient RNAi protocols demonstrate opposite results. PARG silencing was cytoprotective against 
H2O2 und could diminish cytotoxic Ca2+-influx mediated by TRPM2. This PARG-dependent cytosolic 
Ca2+ elevation was required for the translocation of AIF from mitochondria to the nucleus, a hallmark 
of PARP-1-dependent cell death [16, 30] as described earlier [50]. Interestingly, RNAi against PARG 
could not prevent HeLa cells from alkylation-induced cell death [16]. 
4. The Use of Tannins as Inhibitors of PARG 
From various knock-out and knock-down models discussed above, the use of cell-permeable and 
specific PARG inhibitors would offer obvious advantages for research and therapeutic approaches. As 
early as 1989, Tanuma et al. described an inhibitory effect of tannin on purified PARG from human 
placenta [51]. The inhibition was dose-dependent and half maximal with 2.8 µg/mL. In the following 
section, the inhibitory actions observed with a variety of different tannin-like molecules are discussed. 
Hydrolysable tannins are commonly distributed in nature and represent multiple esters of gallic acid 
with glucose (Figure 2). At least 500 different glucogalloyl derivatives have been identified so far with 
molecular sizes varying between ca. 300 and about 10,000 Da [52,53]. 
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Figure 2. Chemical structures of galloyl derivates tested as PARG inhibitors with 
efficiency in cells and/or in vitro. 
 
 
4.1. Tannins Inhibit PARG in Vitro 
All naturally existing tannins are a complex mixture of a variety of distinct molecules with a 
different chemical structure. Much of the work on tannins and PARG has been performed with the 
commercially available tannin cocktail gallotannin, isolated from oaks (Quercus spec.). Some work 
has involved specific tannins from plants as different as Thea sinensis L. [54,55], Saxifraga stolonifera 
Meerb [54-56], Geranium thunbergii Sieg. et Zucc. [55,56], Casuarina stricta Ait. [55,56], Cornus 
officinalis Sieb. et Zucc. [55,56], Rosa rogusa Thunb. [55,56], Coriaria japonica A. Gray [55,56], 
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Tibouchina semidecandra Cogn. [55-57], Hetrocentron roseun A. Br. et Bouch [55,56], and 
Oenothera erythrosepala Borbas. [55,57] indicating the widespread existence of tannins in the plant 
kingdom. The PARG in vitro inhibitory potential of tannins as well as related molecules is summarized 
in Table 1.  
Table 1. Inhibitory potential of tannins, related molecules as well as other known PARG 
inhibitors in enzymatic in vitro assays. 
Compound IC50 (µM) Reference 
Hydrolyzable tannins     
 Gallotannins     
   
Trigalloylglucose 
33.4 ± 3.1 [56] 
   31.8 ± 2.8 [55] 
    3-galloyl-α,β-D-glucose 0.95 ± 0.02 [58] 
    3-galloyl-O-methyl-α,β-D-glucose 7.1 ± 0.05 [58] 
    2-galloyl-O-methyl-α,β-D-glucose 7.2 ± 0.03 [58] 
   
Tetragalloylglucose 
24.8 ± 2.0 [56] 
   24.2 ± 1.9 [55] 
   
Pentagalloylglucose 
17.8 ± 1.2 [56] 
  
  
 18.9 ± 1.1 [55] 
Gallotannin mix 16.8 ± 28.9 [54] 
  Ellagitannins     
   Monomer     
    
Tellimagrandin I 
10.8 ± 0.6 [56] 
    11.9 ± 0.5 [55] 
    
Casuarictin 
13.3 ± 0.7 [56] 
    11.7 ± 0.6 [55] 
    
Geraniin 
18.4 ± 0.7 [56] 
    15.5 ± 0.6 [55] 
   Dimer     
    
Cornusiin A 
5.1 ± 0.2 [56] 
    7.1 ± 0.3 [55] 
    
Rugosin D 
5.8 ± 0.3 [56] 
    6.1 ± 0.4 [55] 
    
Coriariin A 
8.1 ± 0.5 [56] 
    8.5 ± 0.5 [55] 
    
Nobotanin B 
4.8 ± 0.4 [56] 
    4.4 ± 0.3 [55] 
    15 [57] 
    
Oenothein B 
4.8 ± 0.4 [55] 
    3.8 [57] 
   Trimer     
    
Nobotanin E 
1.4 ± 0.2 [56] 
    1.8 ± 0.2 [55] 
   Tetramer     
    
Nobotanin K 
0.44 ± 0.03 [56] 
    0.38 ± 0.03 [55] 
Ellagitannin mix 8.3 ± 12.5 [54] 
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Table 1. Cont. 
Condensed tannins     
  (-)-Epicatechin gallate     
   
Monomer 
>100 [56] 
   >100 [55] 
   
Dimer 
>100 [56] 
   >100 [55] 
   
Trimer 
>100 [56] 
   >100 [55] 
   
Tetramer 
>100 [56] 
   >100 [55] 
Related compounds     
Gallic acid >100 [56] 
Ellagic acid >100 [56] 
(-)-Epicatechin >100 [55] 
(-)-Epigallocatechin >100 [55] 
Benzoic acid >100 [54] 
Glucose >100 [56] 
Other PARG inhibiting molecules    
ADP-HPD 
0.33 [59] 
0.136 [60] 
0.66 [61] 
0.12 [62] 
N-bis-(3-phenylpropyl)-9-oxofluorene-2,7-diamide 
(GPI16552) 
1.7 [63] 
Eosin Y 1.9 [61] 
GPI18214 3 [64] 
Phloxine B 5 [61] 
Ethacridine 7.2 [60] 
Adenosine cyclic 3', 5'-monophosphate 300 [65] 
ADP-ribose 
3200 [57] 
1100 [65] 
Tsai et al. tested the inhibitory effects of tannins on a PARG preparation purified from human 
placenta that was characterized by a KM value of 1.8 ± 0.3 µM and a Vmax of 58 µMol/min/mg protein 
[54]. Using radiolabeled PAR as substrate, they determined the IC50 for ellagitannin (8.3-12.5 µM) and 
gallotannin (16.8-28.9 µM). Interestingly, they show that the degree of PARG inhibition increases with 
the number of galloyl groups, suggesting a specific structure-activity relationship. Furthermore, the 
authors showed that the conjugation of galloyl groups to glucose enhances PARG inhibition. The 
structurally related molecules (-)-epicatechin, (-)-epigallocatechin, and (-)-epigallocatechin gallate 
have little effect on PARG enzyme. Similar results were obtained with equivalent amounts of more 
complex tannins. Gallic acid, ellagic acid, benzoic acid and glucose could be excluded as PARG 
inhibitors even at concentrations of 100 µM [54]. In a follow up study, the inhibitory potential of 
tannins on PARG isolated from the nuclear fraction of murine mamma carcinoma cell line 34I  
(KM = 2.1 ± 0.2 µM, Vmax = 39 µmol/min/mg protein) was investigated [56]. Again gallic acid, ellagic 
acid, and glucose were inefficient as indicated by an IC50 value above 100 µM. The number of galloyl 
groups coupled to glucose seems a determinative factor. In fact, the IC50 values are decreasing for the 
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tested compounds and range from 33.4 ± 3.1 µM for trigalloylglucose to 24.8 ± 0.2 µM for tetra-
galloylglucose, and 17.8 ± 1.2 µM for pentagalloylglucose. The same rule was true if ellagitannins 
were studied. A higher level of molecular complexity promotes PARG inhibition. Monomeric 
ellagitannins are less efficient than dimeric or trimeric species. The most efficient tannin identified in this 
study is the tetrameric ellagitannin nobotanin K with an IC50 of 0.44 ± 0.03 µM. The dimeric ellagitannin 
nobotanin B (Figure 2) was almost ten times less effective in vitro (IC50  = 4.8 ± 0.4 µM) but developed a 
better PARG inhibitory potential when applied in cell culture compared with nobotanin K [56] (see 
next Section). Condensed tannins could not suppress PARG activity regardless of the complexity. The 
knowledge on PARG inhibiting tannins was extended by a study from Aoki et al. [57] using purified 
PARG from the nuclear fraction of calf thymus with a specific activity of 62 µmol/min/mg protein in 
an enzymatic assay with radiolabeled PAR as substrate. In this study, the half-maximal inhibition of 
PARG was determined at 15 µM of nobotanin B. In addition, they identified oenothein B (Figure 2), a 
compound isolated from vine plants, as a functional PARG suppressing molecule with an IC50 value of 
3.8 µM acting in a cell culture model as well [57]. The PARG inhibitory potential of tannins and the 
structure-activity relationship discussed above were confirmed with purified PARG from the nuclear 
fraction of human placenta with a specific activity of 57 µmol/min/mg protein [55]. Trigalloyl-, 
tetragalloyl- and pentagalloylglucose show an increasing degree of PARG suppression depending on 
the number of galloyl groups. Condensed tannins are inactive, while ellagitannins inhibit PARG with 
an increasing efficacy depending on the molecular complexity. More recently, Keil et al. identified the 
PARG inhibiting properties of gallotannin in vitro by thin layer chromatography (TLC) of radiolabeled 
PAR together with nuclear extracts of HeLa S3 cells [66]. In this study, the gallotannin mixture 
contains molecules with 3-5 galloyl groups. 200 µM of gallotannin leads to a 40-fold elevation of 
PAR, indicating the PARG inhibitory effect. Moreover, this phenomenon was dose-dependent ranging 
between 50 and 400 µM of gallotannin. Similar results were shown by Falsig et al. using the TLC 
method as described above [66] but nuclear extracts were replaced by recombinant PARG (aa 378-
976) [67]. As little as 5 µM gallotannin suppressed the majority of PARG enzymatic activity in this 
assay. To overcome the conglomerate nature of gallotannin, Formentini et al. separated all components 
of this tannin cocktail by high-performance liquid chromatography (HPLC) and clarified the chemical 
structure of 14 distinct tannin molecules by mass spectrometry (MS) techniques [58]. The authors 
found 4.2% of gallic acid in the gallotannin mix. Monomeric galloyl glucose derivatives were less 
prominent with values of 2.5% for mono-, 1.6% for tri-, and 3.1% for pentagalloyl glucose. In addition 
to tannins with only one glucose moiety, the dimeric sanguiin H-6 (contains two pentagalloylglucose 
subunits) was identified (Figure 2). Earlier it was shown that sanguiin H-6 is the main ellagitannin in 
fruits of red raspberries (Rubus idaeus L.) [68]. The PARG inhibiting properties of all identified 
galloyl derivatives were tested in an enzymatic assay with radiolabeled PAR as substrate [58]. The 
authors found that 10 µM of 3-galloyl-α,β-D-glucose, 3-galloyl-O-methyl-α,β-D-glucose, 2-galloyl-O-
methyl-α,β-D-glucose as well as sanguiin H-6 were able to suppress about 65% of PARG activity in 
vitro (Figure 2). In contrast, the raw gallotannin mixture inhibits only 25% of PARG. For the three 
monomeric tannins evaluated positively, the IC50 values were determined: 0.95 ± 0.02 µM for 3-galloyl-
α,β-D-glucose, 7.1 ± 0.05 µM for 3-galloyl-O-methyl-α,β-D-glucose, and 7.2 ± 0.03 µM for 2-galloyl-O-
methyl-α,β-D-glucose. These results identify 3-galloyl-α,β-D-glucose as a very potent inhibitory molecule. 
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4.2. Tannins as PARG Inhibitors in Cells and Animals  
Before a detailed view of results of tannins as in vivo PARG inhibitors is discussed, it should be 
considered that the bioavailability of these compounds, i.e. solubility in culture medium and 
permeation into cells are major limiting factors for cell culture and animal use. Very little is known 
about the metabolic fate of tannins (for review see [69]). Gonzalez-Barrio et al. failed to detect either 
raspberry-derived compounds including sanguiin H-6 or any of their metabolites circulating in plasma 
of healthy humans after an acute consumption of 300 g raspberries within 24 h [70]. Likewise, only 
traces of ellagic acid (0.05%) and its metabolite ellagic acid-O-glucuronide (0.03%) were detected in 
urine from healthy volunteers 4-7 h after consumption. Interestingly, epicatechin derivatives were 
shown to reach the plasma of healthy volunteers and could be recovered as mother compounds 
together with their metabolites in the urine of rats and humans [53], ranging up to 31.4% in humans 
after consumption of 350 mL of a low-caloric, polyphenol-rich juice drink [71]. However, none of the 
catechin derivatives tested produced a significant PARG inhibition in vitro (see above). The degree of 
molecular complexity is considered as a major limiting factor for the bioavailability of tannins in the 
body [53]. None of the studies describing tannin derivatives as PARG inhibitors in cells and animals 
have evaluated the bioavailability of their test compounds. The only exception is a study performed by 
Tsai et al. [56]. They determined the bioavailability of nobotanin B in the murine mamma carcinoma 
cell line 34I and found that as little as 0.3% could be recovered 1 h after treatment with 30 µM 
nobotanin B in cell lysate. 
4.2.1. Tannins as PARG Inhibitors in Cell Cultures 
A summary of results from cell culture experiments is presented in Table 2. Oligomeric ellgitannins 
were first tested in [56]. Nobotanin B, E, and K, originally identified as PARG inhibitors in vitro, were 
applied in a 34I cell line (mammarian carcinoma cells isolated from C3H mice). The authors labeled 
intracellular PAR by incorporation of [3H] adenosine (16 h) in the presence or absence of 10 µM of the 
test compounds for 1 h before challenging the cells with 100 nM dexamethasone with or without 
tannins respectively. Degradation of PAR attached to specific proteins (HMG 1, 2, 14, and 17 as well 
as histone H1) was monitored on acetic acid-urea-polyacrylamide-gels. Nobotanin B (Figure 2), but 
not E and K, inhibited the degradation of PAR under these conditions. Interestingly, this effect was 
dependent on the PAR acceptor protein. Whereas PAR degradation of modified HMG 14 and 17 as 
well as histone H1 could be inhibited in a dose-dependent manner by nobotanin B (3, 10 and 30 µM), 
this inhibition failed when PAR was bound to HMG 1 and 2. In addition, the glucocorticoid-dependent 
mRNA synthesis of MMTV (mouse mammary tumor virus) was analyzed in 34I cells 1 h after 100nM 
dexamethasone. In fact, nobotanin B was reducing MMTV mRNA synthesis in a range of 3, 10, and 
30 µM. In a similar setting, oenothein B (Figure 2) was even more efficient than nobotanin B in a 
range of 1 to 50 µM of the tannins [57]. However, oenothein B (30 µM) inhibits the PAR degradation 
of PAR bound on HMG 14 and 17, but not when PAR is attached on the acceptor proteins HMG 1, 2, 
and histone H1. The concept of a negative effect of gallotannin on responsive elements was further 
investigated and confirmed on the 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced HIV 
promoter activity in human leukemia T-cell line Jurkat [72,73]. In 2004 Uchiumi et al. [74], found that 
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gallotannin responsive element(s) are located in the promoter region of the human parg gene of the 
human promyelocytic leukemia cell line HL-60. 
Table 2. Tannin derivatives as PARG inhibitor in cell culture models. 
Author Cell system Stressor Compound Effects 
Tsai 1992 
[56] 
 
34I cells 
(C3H mouse  
mammarian 
carcinoma) 
Dexamethasone  
  
Nobotanin B PAR-degradation of HMG 14, 17 and 
histone H1 blocked, but not on HMG1 and 
HMG2 ; Glucocorticoid-regulated MMTV 
(=Mouse mammary tumor virus) mRNA 
synthesis ↓ ; Bioavailability: 0.3%. 
Aoki 1995 
[57] 
 
34I cells 
(C3H mouse  
mammarian 
carcinoma) 
Dexamethasone  Nobotanin B/ 
Oenothein B 
Glucocorticoid-regulated MMTV mRNA 
synthesis ↓ ; Oenothein B → depoly(ADP- 
ribosylation of HMG 14 and 17 ↓ but not 
HMG 1, 2 and histone H1. 
Ying 2000 
[75] 
 
Murine astro- 
cytes from 
ICR mice 
H2O2  Gallotannin  Preincubated dose-dependent cell death ↓ 
(24 and 72 h) ; No effect under parallel 
treatment with H2O2. 
Ying 2001 
[76] 
 
Neurons 
from Swiss- 
Webster mice  
 
H2O2 
H2O2, MNNG, 
SIN-1, NMDA 
 
Nobotanin B/ 
Gallotannin  
 
Nobotanin B and gallotannin → H2O2- 
induced neuronal cell death (20-24 h) ↓ ;  
Nobotanin B and gallotannin → NMDA  
toxicity ↓ ; Glutamate toxicity ↓.  
Astrocytes 
from Swiss- 
Webster mice  
Cell death ↓ ; Prevents NAD+ drop (10 min) ; 
PAR-degradation (5, 10min) ↓ ; Negligible 
anti-oxidative effect. 
Bakondi 
2004 [77] 
 
HaCaT 
(Human kera- 
tinocytes) 
H2O2, ONOO-  Gallotannin Cytotoxic ; Caspase 3-activity (6 h) ↓ ; No 
effect on PAR accumulation ; PAR-PARP-1 
automodification ↓ ;  NAD+ drop after 0.5, 
1 and 2 h ↓. 
Di Meglio Rat germinal  SIN-1, SNO  Gallotannin DNA repair ↓. 
2004 [78] cells     
Dumitriu 
2004 [79] 
PBMC 
(Human 
peripheral 
blood mono- 
nuclear cells) 
UVB  Gallotannin Inhibition of ABC transporters following 
irradiation ↓.  
  
Falsig Primary astro- H2O2, SIN-1 
MNNG  
CCM (=TNFα,  
IL-1β, IFN-γ) 
Gallotannin Cell death ↓ ; No effect on PAR. 
Cell death ↑  
Gallotannin → nitrite formation from NO ↓ ; 
Gallotannin → iNOS ↑. 
2004 [67] cytes 
  
(C57bl/6jbom 
mice) 
Molecules 2011, 16 
  
1864
Table 2. Cont. 
Keil 2004 
[66] 
HeLa (nuclear 
extracts)  
Gallotannin PAR levels in vitro (3 h) ↑ ; Degradation of 
PAR blocked. 
Rapizzi RAW 264.7 MNNG, LPS,  Gallotannin Per se iNOS ↑ ; COX-2 ↑ ; No induction of  
2004 [80] (Murine macro- IFN-γ, H2O2  IL-1β and of TNFα ; PAR accumulation  
 phages)   (1 h) ↑ without any toxicity ; No effect on 
    basal NAD+ pool ; NAD+ level stabilized 
    after MNNG (1 h) ; No effect on AP-1, IRF-1 
    and pSTAT-1. 
Uchiumi HL-60 12-O-tetradeca- Gallotannin Nuclear PARG activity (3 h) ↓ but not cyto- 
2004 [74] (Human pro- noylphorbol-13-  plasmic ; Basal relative PARG expression ↓. 
 myelocytic leu- acetate   
 kemia cells)      
Erdelyi 
2005 [81] 
 
A549 (Human 
lung adenocar-
cinoma epithelial 
cells) 
TNFα, IL-1β  Gallotannin 4 h after treatment: MCP-1 ↓ ; MIP-1β ↓ ; 
MCP-2 ↓ ; RANTES ↓ ; GCP-2 ↓ ; IL-6 ↓ ; 
ENA-78 ↓ ; fractalkine ↓ ; IL-1α ↓ ; IL-1β ↓ ; 
IL-8 ↓ ; CCR4 ↓ ; CCR5 ↓ by gallotannin, but 
not MIP-3α and CXCR4 ; Gallotannin per se 
induces IL-8 ; Binding of NF-κB to its 
consensus oligonucleotide ↓ ; NF-κB 
phosphorylation and nuclear translocation ↓ ; 
Gallotannin → basal and stress-induced AP-1 ↓ 
; Gallotannin → pJNK ↑ ; p-p38 ↑ ; pATF2 ↑ ; 
pERK1/2 ↑ ; pCREB ↑ ; Protein phosphatases 
1, 2A and PP1 ↓ ; No elevated PAR level. 
Gallotannin is in vitro a strong antioxidant. 
Maruta Mid-S phase    Oenothein B DNA replication activity ↓.  
2007 [82] cell nuclei of     
 HeLa cells       
Formentini HeLa MNNG 3-galloyl-α,β-D- 
glucose 
PAR degradation 15 and 30 min ↓ ; Cell 
death after 3 or 6 h ↓ ; AIF release ↓ (1 h, 
MNNG) ; No DNA strand break induction 
per se. 
2008 [58] 
 
(Human cervical 
cancer cells) 
   
Tikoo 
2010 [83] 
 
H9c2 embryonic   
rat heart 
myoblasts 
Doxorubicin 
  
Gallotannin Cell death ↓ ; Cytoplasmic vacuolization ↓ ; 
Bax ↓ ; Bcl-2 ↑ ; PARP-1 cleavage ↓. 
MDA-MB-231 
breast cancer 
cells 
Toxicity of doxorubicin ↑ ; 
Gallotannin is toxic per se. 
 
Ying et al. investigated the effects of a crude gallotannin extract on cultured astrocytes isolated 
from ICR mice [75]. The cells were stressed with 300 µM of the oxidant H2O2 for 1 h to induce  
PARP-1-dependent cell death. Then the amount of cell death was quantified using the leakage of 
lactate dehydrogenase (LDH) into the culture medium. Gallotannin at concentrations of 100 nM up to 
10 µM efficiently inhibited H2O2-mediated cell death at 24 and 72 h post challenge. Interestingly, this 
effect was only observed, when gallotannin was applied 1 h before the H2O2 treatment, but not when it 
was given concomitantly with H2O2. In cultures of neurons and astrocytes from Swiss-Webster mice, 
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challenged with 100 µM H2O2 (1 h), neurons were protected from cell death when 1 µM nobotanin B 
or 100 µM gallotannin were administered 30 to 60 min to H2O2 [76]. The rate of cell death was assessed 
by propidium iodide (PI) staining of cell nuclei 20 to 24 h after the cytotoxic challenge. Concentrations 
above 10 µM nobotanin B and 100 µM gallotannin were neurotoxic per se. A neuroprotective effect of 
nobotanin B (10 µM) and gallotannin (50 µM) relative to N-methyl-D-aspartate (NMDA)-induced toxicity 
was discovered. Furthermore, astrocytes were treated with the oxidant H2O2 (300 µM, 1 h), the alkylating 
agent MNNG (100 µM, 5-60 min), and the peroxinitrite generator 3-morpholinosydnonimine (SIN-1,  
5 mM, time not specified). Cell survival was measured by LDH content of cell lysates 24 h after the 
cytotoxic challenge. One hour pretreatment with either nobotanin B (0.2 and 2 µM) or 10 µM 
gallotannin protected against H2O2-induced astrocyte death. MNNG- and SIN-1-induced cell death 
could be suppressed with 50 µM gallotannin. As H2O2 and MNNG are PARP activating drugs, Ying et 
al. [76] determined the intracellular level of NAD+, the substrate for PAR synthesis, in astrocytes. 
After 10 min of 100 µM H2O2 or 100 µM MNNG, the drop of NAD+ levels was reduced by 50 µM 
gallotannin. Moreover, this reduced PAR degradation after 5 and 10 min of 100 µM MNNG as tested 
by PAR Western blot analysis. A similar result was obtained with H2O2 (data not shown). Finally, 
intracellular PAR accumulated in neuron/astrocyte co-cultures challenged with 300 µM MNNG for  
15 min when 25 µM gallotannin was applied in parallel [76]. Taken together, these two publications 
by Ying et al., [75, 76] provide evidence that PARG inhibition by the tannins nobotanin B and the 
tannin raw extract gallotannin could have neuroprotective properties. However, the diversity of 
stressors, concentrations of chemicals, incubation times, cell lines and even assays, describing one and 
the same biological endpoint, presented in these publications preclude a final judgment. 
In the year 2004, several publications appeared using gallotannin as PARG inhibitor in a variety of 
mammalian cells. Bakondi et al. investigated H2O2- and ONOO--induced cell death in human adult 
(low calcium high temperature) keratinocytes (HaCaT) [77]. The cells were pretreated with  
50 µM gallotannin for 30 min before a challenge with H2O2 (0.5 or 1 mM) or ONOO- (250 or  
500 µM). After 4 h (and 24 h, data not shown), cell death was quantified with the LDH leakage assay. 
Cells pretreated with gallotannin were less affected by cell death at 4 and 24 h. This observation was 
verified by the analysis of PI stained cell nuclei for the 4 h time point. Note that the extent of the 
cytotoxicity differed markedly between H2O2 and ONOO-. The chosen ONOO- concentrations induced 
less than one third of cellular LDH release compared with the H2O2 conditions. Studying the mode of 
cell death, 300 and 500 µM H2O2, as well as 250 and 500 µM ONOO- induced a caspase 3-like activity 
at about 6 h after the challenge. Interestingly, the values for ONOO- treated cells were higher 
compared with the values of H2O2 treated cells. In all challenge conditions, a pretreatment with 
gallotannin (50 µM, 30 min) diminished the fluorescence signal indicative for caspase 3-like activity. 
Using immunocytochemistry, they found that gallotannin failed to block PAR accumulation after H2O2 
and ONOO-. Moreover, gallotannin inhibited PARP in these settings as assessed by fluorescence 
microscopy of incorporated biotin-labeled NAD+. The authors confirmed their finding of a PARP 
inhibitory effect of gallotannin in an in vitro automodification assay with purified PARP-1 and 
increasing amounts of gallotannin. The drop of cellular NAD+ after H2O2 (500 µM) and ONOO-  
(500 µM) treatment was analyzed 0.5, 1 and 2 h after the cytotoxic insult. Gallotannin could stabilize 
the cellular NAD+ pool at each time point and in both challenging conditions. However, in one of the 
two subsets of NAD+ assays presented in the publication, gallotannin alone increased the level of 
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cellular NAD+ up to at least 150% after 2 h without any oxidative or nitrosative damage. From these 
data the authors conclude that “PARG inhibition by gallotannin maintains the inactive  
poly-ADP-ribosylated form of PARP and thereby breaks the poly(ADP-ribose) cycle” [77]. Di Meglio 
et al. investigated the effects of gallotannin (100 µM, 30 min pretreatment) on the NO donor spermine 
nonoate (SNO, 0.5 mM, 3 h) in rat germinal cells [78]. First, they could confirm the result from 
Bakondi et al. [77] that gallotannin (100 µM) inhibits PARP activity by about 60% reduced turnover 
of PARP-1 bound PAR (automodified/inactive form) in an in vitro assay. By single cell gel 
electrophoresis assay (COMET), gallotannin pretreatment prevented DNA repair in SNO challenged 
primary spermatocytes and round spermatids after a 2 h recovery period. The gallotannin-dependent 
defect in DNA repair capacity was accompanied by an elevated apoptotic rate as determined by 
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay in spermatocytes and 
spermatids [78]. In another study addressing tannin interaction with DNA metabolism [82],  
mid-S phase cell nuclei of HeLa cells were analyzed in vitro for DNA replication activity. They found 
that in mid-S phase cell nuclei, the DNA replication was maintained during DNA repair. 30 µM of 
oenothein B (a potent PARG in vitro inhibitor, see above) blocked efficiently the DNA replication 
activity under these conditions. Recently, Tikoo et al. evaluated an effect of gallotannin on cell death 
induced by doxorubicin in H9c2 embryonic rat heart myoblasts [83]. In this study, the cells were 
treated with 1 or 5 µM doxorubicin for 24 h, then 25 µM gallotannin was applied for a subsequent time 
period of 24 h, and cell death was measured in LDH leakage assay, and the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) metabolic cytotoxicity assay. Under all conditions tested, 
gallotannin treatment rescued almost 100% of the doxorubicin challenged cell population. This finding 
was supported by impaired cytoplasmic vacuolization, decreased bax expression, increased bcl-2 
expression, and a reduced caspase-dependent cleavage of PARP-1, respectively. Interestingly, human 
breast cancer cells (MDA-MB-231) hyperreacted to gallotannin as it induced around 50% cell death 
(MTT) at a concentration of 25 µM. When MDA-MB-231 cells were challenged with doxorubicin (1 
or 5 µM) prior to gallotannin administration, the presence of this tannin mixture elevated the 
cytotoxicity of doxorubicin [83]. These data demonstrate that a broad and even contrary spectrum of 
gallotannin-induced effects strongly depend on the cell line investigated. Rapizzi et al. evaluated the 
effect of gallotannin in murine macrophages (RAW 264.7) [80]. 30 µM gallotannin lead to an 
accumulation of PAR at 1 h without a toxic effect to the cells as assessed by biotinylated NAD+ 
incorporation, LDH, and MTT. In addition, they show a dose-dependent effect of gallotannin in 
stabilizing the decreased cellular NAD+ pool after 1 h of 100 µM MNNG. As a control, 100 µM 
gallotannin per se for 1 h had no influence on the basal NAD+ level. Another level of complexity was 
reached as they made the following interesting observation: gallotannin induced dose-dependent 
expression of iNOS and COX-2. Other tannins (ellagic acid, epicatechin gallate and gallic acid) and 
even more important RNAi against PARG failed to do so. IL-1β and TNFα were not affected by 
gallotannin. Consistent with a gallotanin/PAR-dependent transcriptional activation, elevations of iNOS 
and COX-2 were not related to the activation of NF-κB, AP-1, phospho-STAT-1 and IRF-1, nor 
mRNA stabilization [80]. This was the first evidence that pharmacological PARG inhibition by 
gallotannin alters PAR-dependent gene profiles. Erdelyi et al. investigated the effect of gallotannin  
(30 µM, 30 min pretreatment) on the expression of inflammation related proteins in the human lung 
adenocarcinoma epithelial cell line A549 challenged with either TNFα (20 ng/mL) or IL-1β (5 ng/mL) 
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[81]. The treatment of gallotannin reduced the stress-induced expression (4 h after challenge) of the 
chemokines MCP-1, MIP-1β, RANTES, MCP-2, ENA-78, GCP-2, and fractalkine by at least 50%. 
Moreover, this reduction due to gallotannin was observed for the inflammatory cytokines IL-1α, IL-1β, 
IL-6, IL-8, and for the chemokine receptors CCR4 and CCR5, respectively. Interestingly, stress-
induced MIP-3α and CXCR4 remained unaffected by gallotannin. All these data were collected from 
low-density arrays or PCR. Gallotannin reduced the phosphorylation of p38, ATF2 as well as ERK1/2 
and CREB (Western blot). However, gallotannin per se induced the low-level phosphorylation of p38, 
ATF2, ERK1/2, and CREB. These findings were accompanied by a maximal phosphorylation of JNK 
and c-Jun. Surprisingly, an accumulation of PAR after TNFα or IL-1β in the presence of gallotannin 
was not observed. Therefore, the authors looked into the antioxidant properties of gallotannin in a 
peroxinitrite-driven DHR123 rhodamine converting assay (ABTS decolorization) and found that 
gallotannin is a strong antioxidant, explaining most of the observed results [81]. 
Another pharmacological effect of gallotannin in context with PARG suppression was observed in 
the modulation of a specific drug transporter type [79]. ATP-binding cassette (ABC) transporters are 
responsible for the transport of multiple substrates (e.g. drugs, metabolites, proteins) across cellular 
membranes. It has been shown that UVB irradiation inhibits ABC transporter in human peripheral 
blood mononuclear cells (PBMC) [79]. Dumitriu et al. provided evidence that the presence of 
gallotannin restored the UVB-induced ABC transporter inhibition. The authors concluded that both 
PARG and PARP-1 are necessary for the UVB-mediated ABC transporter suppression [79]. 
As it was obvious that the antioxidative potential of gallotannin has major impact on the outcome of 
experiments done in cells, effects depending on PARG inhibition had to be re-evaluated. Some work 
has been invested in clarifying this question [67, 76, 81]. As early as 1991, Ying et al. described that  
10 µM of gallotannin reduced astrocyte death after 300 µM H2O2 (1 h). By comparison, 100-fold 
higher concentrations of the canonical antioxidants N-tert-butylphenylnitrone (PBN) and N-acetyl- 
cysteine (NAC) were required to match the gallotannin effect, indicating a minor involvement of the 
antioxidative properties of gallotannin in this experimental setting [76]. Falsig et al. invested an entire 
study on the relationship between PARG inhibition by gallotannin and benefits for the cell [67]. They 
used primary astrocytes from C57bl/6jbom mice and confirmed a cytoprotective effect of gallotannin 
against a series of stressors and incubation schemes (H2O2, MNNG, SIN-1). They could not observe an 
accumulation of PAR after gallotannin treatment in astrocytes challenged with 1 mM H2O2 for 1 h. 
Then, they investigated the nitric oxide scavenging potential of gallotannin in a cell-free assay and 
detected a highly efficient and dose-dependent reduction of NO production in the presence of 
gallotannin. The penetration of gallotannin across the membrane was assessed in the Caco-2 (human 
epithelial colorectal adenocarcinoma cell line) intestinal epithelial cell transport assay. No evidence 
was found that gallotannin would penetrate the cell monolayer (data not shown) [67]. Therefore, the 
authors attributed all beneficial effects of gallotannin observed in cell culture to the extracellular 
antioxidant effects of the tannin mixture. 
In 2008, Formentini et al. took tannins back into account [58]. After the in vitro evaluation of 
distinct compounds isolated from the raw tannin extract gallotannin (see above section), they further 
tested the PARG inhibitory potential in HeLa cells challenged with 100 µM MNNG. Interestingly, 
they identified the highly hydrophilic molecule 3-galloyl-1,2-O-isopropylidene-α-D-glucose (Figure 2) 
as a potent inhibitor in cells. Whereas this tannin was inefficient in vitro, it was protective against 
Molecules 2011, 16 
  
1868
MNNG-induced cytotoxicity depending on the treatment scheme as tested by LDH, and MTT assay.  
3-galloyl-1,2-O-isopropylidene-α-D-glucose was able to inhibit PAR degradation induced by 100 µM 
MNNG as detected by Western blot and immunofluorescense microscopy techniques. Moreover a 
treatment of cells with 100 µM 3-galloyl-1,2-O-isopropylidene-α-D-glucose was sufficient to reduce 
MNNG-mediated translocation of AIF from mitochondria (4 h after treatment). AIF translocation from 
mitochondria to the cell nucleus was identified as a crucial step in PAR mediated cell death [16, 30, 
50, 84-87]. The application of this tannin-like compound did not induce DNA strand breaks (COMET 
assay) and had only slight cytotoxic effects pending on the dose and treatment scheme. Interestingly, 
3-galloyl-1,2-O-isopropylidene-α-D-glucose was inefficient to inhibit PARG in vitro. Therefore, the 
authors suggested a metabolic activation step within the cell by hitherto unidentified hydrolases, 
generating the metabolite 3-galloyl-α,β-D-glucose, that was identified earlier as a very potent PARG 
inhibitor in vitro (Figure 2) [58]. 
4.2.2. PARG Inhibitory Effects of Tannins in Animal Experiments 
Since there is substantial doubt about the causality of a specific inhibition of PARG by tannin-like 
molecules in cell culture (see above), the following observations obtained in animal experiments 
should be considered with caution. A parenteral application mode for tannins in all animal studies was 
used [83, 88-91]. Thus, it was possible to by-pass the low degree of oral bioavailability. The results of 
experiments with gallotannin as PARG inhibitor in animals are summarized in Table 3. In 2007  
Wei et al. published a study with the raw tannin mixture gallotannin, performed in male Sprague-
Dawley rats as a model of ischemia/reperfusion (I/R) injury [91]. The rats were subjected to 
intraluminal middle cerebral artery occlusion (MCAo) with subsequent reperfusion 2 h after the injury. 
They chose intranasal applications of gallotannin to ensure the direct by-pass of the blood-brain 
barrier. In the first set of experiments, they found that 50 mg/kg body weight gallotannin alters some 
physiological markers (data not shown), indicating a toxic potential of the drug when administered 
intranasally [91]. Therefore, they took a 25 mg/kg concentration, not altering body temperature, blood 
pressure, blood CO2 levels and pH. When gallotannin was applied 2 h after ischemia, they observed a 
protective effect of the drug mixture. 24 h after ischemia induction, the infarct size decreased nearly 
70% in the brain and I/R-dependent neurological defects were reduced in gallotannin treated rats, 
respectively. These levels were still maintained 72 h after ischemia. In this setting, gallotannin 
increased nuclear PAR accumulation in the penumbra area of the brain 4 and 16 h after ischemia as 
assessed by immunofluorescence microscopy. Moreover, the translocation of AIF from mitochondria 
to cell nuclei − a marker for ongoing cell death − was prevented by gallotannin at 4 and 16 h post I/R 
damage. Even if gallotanin was applied intranasally 5 h post injury, infarct size and neurological 
defects were less abundant compared to control rats three days after I/R. Interestingly, the intravenous 
(i.v.) administration of 12.5 mg gallotannin did not result in any effects. The higher concentration of  
25 mg/kg, that was efficient to reduce I/R-mediated insults when given intranasally, led to significantly 
increased death rate of the rats [91]. 
Tikoo et al. investigated the effects of gallotannin in a cisplatin-based model of nephrotoxicity in 
male Sprague-Dawley rats and came up with conflicting results pending on the time window of 
gallotannin administration [89]. 
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Table 3. Effects of the potential PARG inhibitor gallotannin in animals. 
Author Animals Model Compound Key findings 
Tikoo 
2007 
[89] 
Male  
Sprague- 
Dawley 
Rats  
  
Model of 
nephrotoxicity 
(Cisplatin) 
  
  
Gallotannin 
(intraperito- 
 neal) 
  
  
Co-treatment of gallotannin → nephrotoxicity ↑:  
(BUN ↑ ; Plasma creatinine ↑ ; Plasma albumin ↑) ;  
PARP-1 cleavage ↓ ; Tubular damage ↓. Post-
treatment → toxicity ↓: (BUN ↓ ; Plasma 
creatinine ↓ ; Plasma albumin ↓) ; Tubular damage ↓ 
; PARP-1 cleavage ↓.  
Tikoo 
2008 
[90] 
Male  
Swiss 
albino 
mice 
Antiretroviral drug 
(Azidothymidine) 
  
Gallotannin 
(intraperito- 
 neal) 
Gallotannin is hepatoprotective after azidothymidine.  
Oxidative stress ↓ (TBARS ↓ ,  GSH ↓ ) ; ALT ↓ ;  
AST ↓ ; Alkaline phosphatase ↓ ; Micronuclei for- 
mation ↓ ; Vacuolization ↓ ; Fine inflammatory in- 
filtrations ↓ ; Fatty degeneration of hepatocytes ↓ ;   
Histone acetylation ↓ ; PARP-1 cleavage (89 kDa) ↓. 
Wei 
2007 
[91] 
Male  
Sprague- 
Dawley 
Rats 
 
Model for ischemia/ 
reperfusion injury 
(Intraluminal middle 
cerebral artery oc- 
clusion)  
Gallotannin 
(intranasal)  
  
  
Gallotannin protects against ischemia/reperfusion  
size ↓ ; Neurological deficits ↓ ; Nuclear PAR ↑  
(4 and 16 h) ; AIF translocation ↓ (4 and 16 h). 
5 h gallotannin after reperfusion: Infarct size ↓ ; 
Neurological deficits ↓.  
Chandak 
2009 
[88] 
Male  
Sprague- 
Dawley 
Rats 
Model of diabetes I 
(Streptozotocin) 
  
  
Gallotannin 
(intraperito- 
 neal) 
  
No effect on body weight, plasma glucose, BUN  
and urine proteine. Glomerular hypertrophy ↓ ; 
Plasma creatinine ↓ ; PARP-1 cleavage (24 kDa) ↓. 
Tikoo Female Breast cancer model Gallotannin Gallotannin shows protection against doxorubicin-  
2010 Sprague- (7,12-dimethyl  (intraperito- induced cardiotoxicity. Heart weight ↑ ; Relative  
[83] Dawley benz(a)anthracene/  neal) heart weight ↑ ; TBARS ↑ ; Bax expression ↓ ; 
 Rats doxorubicin)   Plasma LDH ↓ ; Cytoplasmic vacuolization ↓ ; 
    Myofibrils ↑ ; PARP-1 116 kDa + 89 kDa ↓ ; p53 ↑ ; 
    But potentiates doxorubicin toxicity in breast tumors. 
 
The animals were treated with 5 mg/kg cisplatin intraperitoneally (i.p.) to induce 
nephropathologies. Gallotannin (10 mg/kg i.p.) was either applied directly or 3 days after cisplatin. A 
co-administration of gallotannin increased all markers of nephrotoxicity. The authors determined 
higher levels of blood urea nitrogen (BUN), plasma creatinine, and plasma albumin. Moreover, 
histopathological examinations revealed an increased tubular damage with a concomitant occurrence 
of caspase-dependent PARP-1 cleavage products as assessed on Western blot. Comparative studies 
with a reduced dose of cisplatin (1.5 µg/kg i.p.) developed almost similar nephrotoxicity in the 
presence of gallotannin. Interestingly, post-treatment of gallotannin (3 d after 5 mg/kg cisplatin i.p.) 
decreased nephrotoxicity as tested with determinations of BUN, plasma creatinine, plasma albumin, 
histopathologically evaluated tubular damage as well as a reduced amount of PARP-1 cleavage. It is 
noteworthy that gallotannin alone had no impact on body weight, BUN, creatinine, and albumin [89]. 
The effect of gallotanin on the antiretroviral drug azidothymidine [AZT, 28 d, daily 800 mg/kg per 
os (p.o.)] treated male Swiss albino mice was investigated by Tikoo et al. in 2008 [90]. As expected 
AZT administration led to severe hepatotoxic effects in mice. Gallotannin was given in parallel  
(28 d, daily 5 mg/kg i.p.) and showed hepatoprotective potential regarding AZT-induced liver insults. 
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It normalized markers for oxidative stress in the liver [thiobarbituric acid reactive substances 
(TBARS), glutathione (GSH)]. In addition, the co-administration of gallotannin together with AZT 
resulted in a reduction of the following blood enzymes indicative for hepatotoxicity: alkaline 
phosphatase as well as the aminotransferases ALT and AST. AZT induces micronuclei formation in 
the peripheral blood due to its potential clastogenic and aneugenic activity. The administration of 
gallotannin decreased the number of micronuclei, respectively. Histopathologically, gallotannin 
increased the level of vacuolization, inflammatory infiltrations, and fatty degeneration in hepatocytes 
[90]. At the molecular level, gallotannin reduced the AZT-induced elevation of PARG protein in 
murine livers. This was determined by immunofluorescence stainings. As all antibodies against PARG 
developed so far failed to detect PARG protein in a cellular context, this result should be rated with 
caution. Furthermore, they observed a reduced portion of PARP-1 cleavage products in livers of 
gallotannin treated mice (Western blot) and a reduced amount of AZT-induced histone acetylation 
(data not shown). 
A protective effect of gallotannin on doxorubicin-induced cardiotoxicity was observed in a breast 
cancer model in female Sprague-Dawley rats by Tikoo et al. [83] in 2010. Rats were treated with the 
carcinogen 7,12-dimethylbenz(a)anthracene (DMBA, 100 mg/kg p.o.) to develop a breast cancer 
phenotype. Then, the animals were exposed to doxorubicin (2.5 mg/kg, once per week for 5 weeks i.p.) 
with a subsequent administration of gallotannin (10 mg/kg, 5 d, daily, i.p.). As expected, animals 
challenged with doxorubicin showed a decline in cardiac systolic function and atrophy of the cardiac 
muscle. The application of gallotannin protected against doxorubicin-induced cardiotoxicity. The 
authors found improved heart weights, relative heart weights and decreased TBARS as marker for 
oxidative stress in the rat hearts. Moreover, gallotannin reduced the plasma level of LDH and partially 
restored myocardial morphology. At the molecular level, they observed that gallotannin reduced 
doxorubicin-induced bax expression in the hearts of the rats (Western blot) and a further increase of 
doxorubicin-induced p53 levels when the rats were treated subsequently with gallotannin [83]. 
However, gallotannin further potentiates the anti-cancer activity of doxorubicin in breast tumors, as 
assessed in the same animals. 
Chandak et al. investigated male Sprague-Dawley rats in a streptozotocin (STZ)-induced model of 
diabetes type I (single i.p. injection of 55 mg/kg) [88]. After four weeks of STZ administration 
gallotannin was injected daily for four weeks (20 mg/kg i.p.) and clinical parameters were assessed. 
Gallotannin could significantly reduce the plasma creatinine level from 0.84 ± 0.10 mg/dl to  
0.66 ± 0.44 mg/dl (around 0.4 mg/dL in control animals). The application of the tannin mixture had no 
effect on body weight, plasma glucose, BUN and urine protein in STZ-induced diabetes. By contrast, 
they found a marked reduction of glomerular hypertrophy by histopathology in gallotannin treated rats 
and a slightly reduced portion of the PARP-1 24 kDa cleavage fragment in the diabetic kidney [88]. 
5. Conclusions 
The concept that tannin-like molecules could inhibit a key enzyme in DNA damage checkpoint 
signaling has attracted a lot of medical attention. The enzyme in question is PARG, which has been 
recently shown to play an integral role in the initiation of cell death. As reviewed here, some distinct 
compounds of the heterogeneous group of tannins have been identified as PARG inhibitors, but this 
action can only be observed in vitro and to a variable extent in cell cultures. The problem is that 
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tannins have a limited bioavailability in biological systems due to their solubility and membrane 
permeation. Thus, the available literature on tannin actions in biological systems has to be interpreted 
with caution. Only few studies have verified the presence of PARG inhibitory principle within cells, 
either by analyzing the parent compound or a metabolite. Nevertheless, biological activity has been 
reported in both cells and animals. It is very likely that several of these actions are unrelated to PARG 
inhibition, but rather a consequence of the well documented antioxidative [52,53,69] or some other 
extracellular activities. 
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